VLA-4 as a Central Target for Modulating Neuroinflammatory Disorders.
The complex steps leading to the central nervous system (CNS) inflammation and the progress to neuroinflammatory and neurodegenerative disorders have opened up new research and intervention avenues. This review focuses on the therapeutic targeting of the VLA-4 integrin to discuss the clear-cut effect on immune cell trafficking into brain tissues. Besides, we explore the possibility that blocking VLA-4 may have a relevant impact on nonmigratory activities of immune cells, such as antigen presentation and T-cell differentiation, during the neuroinflammatory process. Lastly, the recent refinement of computational techniques is highlighted as a way to increase specificity and to reduce the detrimental side effects of VLA-4 immunotherapies aiming at developing better clinical interventions.
['Jurberg|Arnon Dias|AD|', 'Chaves|Beatriz|B|', 'Pinho|Lia Gonçalves|LG|', 'da Silva|João Hermínio Martins|JHM|', 'Savino|Wilson|W|', 'Cotta-de-Almeida|Vinicius|V|']
Integrin Migration Multiple sclerosis Natalizumab T cells